Drugs / Intravenous Immunoglobulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07861776 Comparator | Oct 2026 → Sep 2029 expected | secondary hemophagocytic lymphohistiocytosis | Post Graduate Institute of Medical Education and Research, Chandigarh | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous Immunoglobulin | “Intravenous Immunoglobulin (IVIg) therapy” NCT07861776 ↗ |
| Known as | IVIg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07861776 ↗ |
| Modality | Protein / enzyme biologic | “intravenous Immunoglobulin (IVIg) therapy” NCT07861776 ↗ |